<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154732">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01929291</url>
  </required_header>
  <id_info>
    <org_study_id>115374</org_study_id>
    <nct_id>NCT01929291</nct_id>
  </id_info>
  <brief_title>Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea</brief_title>
  <official_title>Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Reduced Antigen Content Diphtheria-tetanus Toxoids and Acellular Pertussis Vaccine (dTPa), Boostrix When Administered According to the Approved Prescribing Information in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Korea: Korea Food &amp; Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect safety information from pre-adolescents, adolescents
      and adults after Boostrix vaccination is administered according to the approved prescribing
      information in Korea.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>During the 30-day (Day 0 - Day 29) follow-up period after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>Starting at Visit 1 in the post-marketing surveillance up to 30 days (Day 0 to Day 29) after the vaccine is administered</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Tetanus</condition>
  <condition>Acellular Pertussis</condition>
  <condition>Diphtheria</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Pre-adolescents (aged (≥11 years to &lt;12 years), adolescents (aged ≥12 to &lt;19 years) and adults (aged ≥19 years) who received Boostrix as a part of routine practice at a private clinic or hospital in Korea.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Boostrix</intervention_name>
    <description>Single intramuscular injection</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>dTPa vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Safety data collection</intervention_name>
    <description>Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pre-adolescents, adolescents and adults who receive Boostrix as a part of routine practice
        at a private clinic or hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written or signed informed consent obtained from the subject/ subject's
             parent(s)/Legally Acceptable Representative(s) of the child. Korean male or female
             subjects who were recently vaccinated or eligible to receive Boostrix according to
             the locally approved Prescribing Information.

        Exclusion Criteria:

          -  Those who are not eligible for vaccination according to the local Prescribing
             Information.

          -  Child in care.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwon-si</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>December 5, 2013</lastchanged_date>
  <firstreceived_date>August 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Korea</keyword>
  <keyword>Post-marketing surveillance</keyword>
  <keyword>Boostrix</keyword>
  <keyword>Prescribing information</keyword>
  <keyword>Safety</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
